Apotex Inc. Acquires Topgen E.S.V. in Belgium from Zambon
"This acquisition represents an important milestone for Apotex International as it extends the organization's footprint in Europe and will be a launching pad for many E.U. products currently in the Apotex development pipeline," stated Andrew Kay, Apotex International President.
"The sale of Topgen furthers Zambon's strategy of focusing its Belgian operations on developing its portfolio of branded products, while simultaneously strengthening our relationship with Apotex, which is already a partner of Zambon and Chiesi in Italy through Doc Generici S.r.l.," explained Roberto Consonni, CEO of Zambon's Pharma Business.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.